U.S. Markets open in 3 hrs 24 mins
  • S&P Futures

    4,224.00
    +1.75 (+0.04%)
     
  • Dow Futures

    33,835.00
    +30.00 (+0.09%)
     
  • Nasdaq Futures

    14,199.00
    +33.50 (+0.24%)
     
  • Russell 2000 Futures

    2,280.40
    -4.10 (-0.18%)
     
  • Crude Oil

    70.70
    -0.34 (-0.48%)
     
  • Gold

    1,795.50
    +20.70 (+1.17%)
     
  • Silver

    26.50
    +0.65 (+2.51%)
     
  • EUR/USD

    1.1915
    +0.0004 (+0.0358%)
     
  • 10-Yr Bond

    1.5110
    0.0000 (0.00%)
     
  • Vix

    17.43
    -0.72 (-3.97%)
     
  • GBP/USD

    1.3893
    -0.0031 (-0.2223%)
     
  • USD/JPY

    110.1340
    -0.0970 (-0.0880%)
     
  • BTC-USD

    37,418.02
    -2,037.21 (-5.16%)
     
  • CMC Crypto 200

    926.48
    -43.40 (-4.47%)
     
  • FTSE 100

    7,113.79
    -39.64 (-0.55%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Catalent Inc (NYSE: CTLT) has been expanding rapidly in next-gen cell therapies, and now it has added another facility in Belgium as part of its plan to bolster its E.U. hub.

  • Catalent has acquired Promethera’s Hepatic Cell Therapy Support SA (HCTS) subsidiary and its 32,40-square-foot facility in Gosselies, Belgium. The financial terms of the deal were not disclosed.

  • The pickup will help Catalent move into plasmid DNA production, complementing its recent purchase of Delphi Genetics, located at Catalent’s growing campus in Gosselies. That buyout added a 17,000-square-foot facility.

  • The HCTS site comes equipped with existing cleanroom infrastructure, process development, quality control laboratories, and warehouse space and will be equipped to provide pDNA manufacturing up to a 500-liter scale, Catalent said.

  • Catalent expects to start outfitting the facility immediately and plans to add more than 200 jobs at the facility, the company said.

  • Price Action: CTLT shares are down 1.35% at $105.04 during market trading hours on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.